Search

Shark liver oil

However the major component is considered to be squalene, which may range up to 90% of the shark oil, depending on the species. … The 3 main targeted species are the deep sea shark (Centrophorus squamosus), the dogfish (Sqaulus acanthias), and the basking shark (Cetorhinus maximus).

Valaciclovir

It was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline [L5671]. Valacyclovir is the L-valine ester of aciclovir. … One major use of valacyclovir is the treatment of genital herpes episodes or outbreaks.

Ceftobiprole

The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European … Union primarily due to data quality issues in pivotal clinical studies.

Gonadorelin

GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.

Equine Botulinum Neurotoxin A Immune FAB2

It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.

Octyl triazone

Bexarotene

Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.

Hydroxyzine

Hydroxyzine is a first-generation histamine H₁-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties. … [L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect.

Tovorafenib

[A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. … [A263602] Tovorafenib inhibits BRAF and blocks dysregulated signalling pathways related to cancer cell growth and survival.[L50587]

Equine Botulinum Neurotoxin F Immune FAB2

It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients.